![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Pharmazeutisches Institut, Tübingen, Germany
We have shown before that the human immunodeficiency virus (HIV) protease inhibitors ritonavir and nelfinavir, but not indinavir, suppress insulin secretion from mouse pancreatic B-cells via reduction of the cytosolic free calcium concentration ([Ca2+]c). This was not because of an effect on ATP-dependent K+ channels (KATP channels) or L-type Ca2+ channels. The study was intended to elucidate the mechanisms by which distinct HIV protease inhibitors decrease [Ca2+]c and thus evoke their adverse side effect on insulin release. Membrane potential and whole-cell currents were measured with the patch-clamp technique, and [Ca2+]c was determined with a fluorescence dye. Ritonavir and nelfinavir both inhibited the same component(s) of voltage-dependent K+ currents with a concomitant change in action potential wave form, whereas indinavir was ineffective. Comparison with other blockers of voltage-dependent K+ currents revealed that suppression of distinct noninactivating current component(s) altered action potential wave form and decreased [Ca2+]c similar to ritonavir and nelfinavir, whereas blockage of inactivating component(s) was without effect. Complete inhibition of voltage-dependent K+ currents by 80 mM TEA+ drastically increased [Ca2+]c, demonstrating that voltage-dependent K+ channels are not the sole target of ritonavir and nelfinavir. Accordingly, the Ca2+-lowering effect of ritonavir was preserved in the presence of 80 mM TEA+. This effect was mimicked by the anion channel blocker 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS). Consequentially, ritonavir and nelfinavir inhibited a DIDS-sensitive anion current in B-cells. We suggest that ritonavir and nelfinavir decrease insulin secretion by inhibition of voltage-dependent K+ channels and anion channels, which are essential to provide counterion currents for Ca2+ influx across the plasma membrane.
Address correspondence to: Dr. Peter Krippeit-Drews, Pharmazeutisches Institut, Auf der Morgenstelle 8, D-72076 Tübingen, Germany. E-mail: peter.krippeit-drews{at}uni-tuebingen.de